NO951641D0 - Transkripsjonsfaktor - Google Patents

Transkripsjonsfaktor

Info

Publication number
NO951641D0
NO951641D0 NO951641A NO951641A NO951641D0 NO 951641 D0 NO951641 D0 NO 951641D0 NO 951641 A NO951641 A NO 951641A NO 951641 A NO951641 A NO 951641A NO 951641 D0 NO951641 D0 NO 951641D0
Authority
NO
Norway
Prior art keywords
protein
transcription factor
seq
fragment
isolated form
Prior art date
Application number
NO951641A
Other languages
English (en)
Other versions
NO323532B1 (no
NO951641L (no
Inventor
Nicholas Barrie La Thangue
Original Assignee
Medical Res Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929222715A external-priority patent/GB9222715D0/en
Priority claimed from GB939316206A external-priority patent/GB9316206D0/en
Application filed by Medical Res Council filed Critical Medical Res Council
Publication of NO951641D0 publication Critical patent/NO951641D0/no
Publication of NO951641L publication Critical patent/NO951641L/no
Publication of NO323532B1 publication Critical patent/NO323532B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
NO19951641A 1992-10-29 1995-04-28 Fremgangsmate for identifisering av kjemoterapeutiske midler ved bruk av transkripsjonsfaktor DP-1 NO323532B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB929222715A GB9222715D0 (en) 1992-10-29 1992-10-29 Transcription factor
GB939316206A GB9316206D0 (en) 1993-08-05 1993-08-05 Transcription factor
PCT/GB1993/002227 WO1994010307A1 (en) 1992-10-29 1993-10-29 Transcription factor dp-1

Publications (3)

Publication Number Publication Date
NO951641D0 true NO951641D0 (no) 1995-04-28
NO951641L NO951641L (no) 1995-06-29
NO323532B1 NO323532B1 (no) 2007-06-04

Family

ID=26301878

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19951641A NO323532B1 (no) 1992-10-29 1995-04-28 Fremgangsmate for identifisering av kjemoterapeutiske midler ved bruk av transkripsjonsfaktor DP-1

Country Status (12)

Country Link
US (2) US5863757A (no)
EP (2) EP0905236A1 (no)
JP (1) JP3633616B2 (no)
KR (1) KR950704484A (no)
AT (1) ATE181360T1 (no)
AU (1) AU675678B2 (no)
CA (1) CA2148258A1 (no)
DE (1) DE69325383T2 (no)
DK (1) DK0669976T3 (no)
NO (1) NO323532B1 (no)
NZ (1) NZ257181A (no)
WO (1) WO1994010307A1 (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1340505A3 (en) * 1993-10-29 2004-07-14 The Brigham And Women's Hospital, Inc. Therapeutic use of cis-element decoys in vivo
GB9413327D0 (en) * 1994-07-01 1994-08-24 Medical Res Council Assay for inhibitors of dp-1
US6045999A (en) * 1994-11-15 2000-04-04 Prolifix Limited Transcription factor E2F-4
US6303335B1 (en) 1994-11-15 2001-10-16 Prolifix Limited Transcription factor E2F-4
GB9502873D0 (en) * 1995-02-14 1995-04-05 Medical Res Council Transcription factor
US5705350A (en) * 1995-08-29 1998-01-06 Duke University Transcription factor complexes in senescent cells
GB9608143D0 (en) * 1996-04-19 1996-06-26 Ver Nl Kanker Inst Assay
GB9610195D0 (en) * 1996-05-15 1996-07-24 Medical Res Council Assay
US6159691A (en) * 1996-05-15 2000-12-12 Prolifix Limited Assay for a putative regulator of cell cycle progression
FR2750705B1 (fr) * 1996-07-04 1998-10-30 Centre Nat Rech Scient Systeme de detection des interactions proteine-proteine
CA2267188A1 (en) * 1996-09-30 1998-04-09 Kyowa Hakko Kogyo Co., Ltd. E2f activity inhibiting compound
US6387649B1 (en) 1996-09-30 2002-05-14 Prolifix Limited Assay for a regulator of cell cycle progression
GB9626589D0 (en) * 1996-12-20 1997-02-05 Prolifix Ltd Peptides
US5932425A (en) * 1997-02-18 1999-08-03 Signal Pharmaceuticals, Inc. Compositions and methods for modulating cellular NF-κB activation
ATE350472T1 (de) 1997-10-21 2007-01-15 Univ Glasgow Jmy, mit-aktivator für p300/cbp, dafür kodierendenucleinsäure und deren verwendungen
AU3478399A (en) * 1998-04-09 1999-11-01 E.I. Du Pont De Nemours And Company Cell cycle regulatory proteins cdc-16, dp-1, dp-2 and e2f from plants
AU6976300A (en) * 1999-09-16 2001-04-17 Mcgill University Methods for modulating cell proliferation
AU7781400A (en) * 1999-09-24 2001-04-24 Consejo Superior De Investigaciones Cientificas Wheat dp proteins and uses thereof
GB9923306D0 (en) 1999-10-01 1999-12-08 Isis Innovation Diagnostic and therapeutic epitope, and transgenic plant
US20030225012A1 (en) * 2002-05-31 2003-12-04 Isis Pharmaceuticals Inc. Antisense modulation of transcription factor DP-1 expression
GB0212885D0 (en) 2002-06-05 2002-07-17 Isis Innovation Therapeutic epitopes and uses thereof
CA2564521C (en) 2004-04-28 2017-04-11 Btg International Limited Epitopes related to coeliac disease
US10105437B2 (en) 2004-04-28 2018-10-23 Btg International Limited Epitopes related to coeliac disease

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3609693A (en) * 1992-01-29 1993-09-01 Duke University Method of assaying for the oncogenic state of cells

Also Published As

Publication number Publication date
DK0669976T3 (da) 2000-01-10
DE69325383D1 (de) 1999-07-22
US6150116A (en) 2000-11-21
WO1994010307A1 (en) 1994-05-11
NO323532B1 (no) 2007-06-04
JP3633616B2 (ja) 2005-03-30
CA2148258A1 (en) 1994-05-11
NO951641L (no) 1995-06-29
US5863757A (en) 1999-01-26
EP0669976B1 (en) 1999-06-16
DE69325383T2 (de) 1999-11-25
ATE181360T1 (de) 1999-07-15
EP0669976A1 (en) 1995-09-06
NZ257181A (en) 1997-07-27
KR950704484A (ko) 1995-11-20
AU675678B2 (en) 1997-02-13
JPH08503128A (ja) 1996-04-09
AU5343994A (en) 1994-05-24
EP0905236A1 (en) 1999-03-31

Similar Documents

Publication Publication Date Title
NO951641D0 (no) Transkripsjonsfaktor
ATE491029T1 (de) Fibroblasten-wachstumsfaktoren-homologe
ATE295414T1 (de) Menschliche ctla-8 und verwendung von ctla-8 ähnlichen proteinen
ATE123806T1 (de) Genetisch geformte neue pflanzenphenotypen.
EP1734121A3 (en) Genetically engineered human-derived Kunitz domains that inhibit human neutrophil elastase
CA2163454A1 (en) Regulation of plant growth
NO882341L (no) Ekspresjon av humant proapolipoprotein a-i.
ATE226634T1 (de) Fibronektin bindendes protein
IT8119760A0 (it) Polipeptide prodotto microbiologicamente con la sequenza di aminoacidi dell'interferone umano, dna e plasmidi che codificano per questa sequenza, microorganismi che contengono queste informazioni genetiche e processo per la loro preparazione.
KR100295606B1 (no)
NO177863C (no) Fremgangsmåte for fremstilling av rekombinant humant IFN-type I, IFN1, IFN-pseudo-2, -3, og -4, samt ekspresjonsvektorer
DK0951837T3 (da) Bioaktive peptider samt anvendelse og fremgangsmåde til fremstilling af sådanne
ATE534742T1 (de) Polypeptide und nukleinsäuren von phorphorymonas gingivalis
NO882380D0 (no) Fibfonektin-bindende protein, samt fremstilling derav.
ES2093688T3 (es) Deteccion especifica del mycobacterium tuberculosis.
DE69229718D1 (de) Mutierte Form von dem Beta-Amyloidprecursor Proteine Gen
FI940036A (fi) Nukleotidisekvenssejä ja sykloheksimidiresistenssejä proteiineja
DE3582136D1 (de) Gen fuer ein protein mit insektizider wirkung.
IT8119759A0 (it) Umano, dna e plasmidi che polipeptide prodotto codificano per questa sequenza, microbiologicamente con la sequenza microorganismi che contengono di aminoacidi dell'interferone queste informazioni genetiche e processo per la loro preparazione.
DE3881123D1 (de) Klonieren von fuer einen antibakteriellen polypeptidvorlaeufer kodierender dna und expression des vorlaeufers.
DE68910036D1 (de) Luciferase-Gen und neue rekombinante DNA sowie Verfahren zur Herstellung von Luciferase.
CA2192260A1 (en) Dna fragment encoding a protein involved in fatty aldehyde decarbonylase activity, recombinant molecules comprising said fragment and a method for obtaining transformed bacterial cells and plants
DE3889143D1 (de) Verfahren zur Herstellung von L-Phenylalanin durch rekombinantes E.coli.
Trofimova et al. The mechanism of formaldehyde cytotoxic action on cultured mammalian cells.
Borodin et al. Genes coding for bacterial RNA polymerase. III. Use of modified method of Sanger for sequencing C-terminal region of rpoB gene, intercistron region, rpoBC operon, and N-terminal region of rpoC gene of Pseudomonas putida.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees